GlassScriptPhysician profile
Norma Henriquez
NPI 1053340976
$4,061.91
in general payments reported to CMS, 2019-2025
18 companies · $291 in 2025
The $291 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $284 · 2020: $181 · 2021: $521 · 2022: $464 · 2023: $1,940 · 2024: $381 · 2025: $291.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,872 · Travel and Lodging: $713 · Education: $27.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,872.03 |
| Travel and Lodging | $712.72 |
| Education | $27.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neuronetics, INC. | $1,162.57 | 2023 | Neurostar Tms Therapy System |
| Abbvie INC. | $1,032.35 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $677.59 | 2020-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $240.94 | 2019-2024 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Allergan, INC. | $235.99 | 2019-2020 | |
| Alkermes, INC. | $164.71 | 2019-2025 | Aristada, Lybalvi |
| Takeda Pharmaceuticals U.S.A., INC. | $96.58 | 2021-2025 | Trintellix |
| Axsome Therapeutics, INC. | $82.63 | 2024-2025 | Auvelity |
| Almatica Pharma LLC | $75.48 | 2022-2025 | Loreev Xr |
| Janssen Pharmaceuticals, INC | $69.38 | 2019-2025 | Invega Sustenna, Invega Trinza |
| E.R. Squibb & Sons, L.L.C. | $52.93 | 2024 | Cobenfy |
| Teva Pharmaceuticals USA, INC. | $34.39 | 2023-2024 | Austedo, Austedo Xr |
| Neurocrine Biosciences, INC. | $30.86 | 2023 | |
| Vanda Pharmaceuticals INC. | $25.13 | 2025 | Hetlioz, Fanapt |
| Orexo US, INC. | $24.38 | 2024 | Zubsolv |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $21.76 | 2022 | |
| Indivior INC. | $18.61 | 2020 | |
| Idorsia Pharmaceuticals US INC | $15.63 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Norma Henriquez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.